传感器类型
表面等离子共振(SPR)生物传感器
检测对象
片段库化合物(fragment library compounds,含溴茚酮片段)、奈韦拉平(nevirapine)、德拉维定(delavirdine);样品基质为PBS/5% DMSO/0.05% Tween 20缓冲液及96孔酶反应液。
检测原理
重组HIV-1 RT经胺偶联固定于CM5 SPR芯片表面。片段库化合物随PBS/5% DMSO/0.05% Tween 20流经芯片,若结合到NNRTI结合位点(NNIBP),芯片表面结合质量增加,引起局部折射率变化,SPR共振角偏移,形成sensorgram。稳态响应随片段浓度升高而增大,按Langmuir模型拟合可得KD;与nevirapine共注时,若片段竞争同一位点,响应下降。正交酶抑制实验中,片段抑制HIV-1 RT聚合酶活性,使比色底物显色减少,405 nm吸光度降低,按修正Langmuir方程拟合IC50。方法无化学放大,依赖高浓度片段和参考扣除/溶剂校正。
检测灵敏度
原文未报告LOD、线性范围、灵敏度斜率或相关系数。
效应效果
从1040个片段中初筛得165个,人工审查后保留96个;20个与nevirapine竞争,27个酶抑制IC50<1 mM,最终10个同时命中,复测排除2个假阳性。片段4对wt HIV-1 RT的KD为270 μM、IC50为4 μM,对K103N、Y181C、L100I的IC50分别为16、16、25 μM,是唯一对四种变体均重复抑制>50%且IC50<25 μM的片段;片段4和5对四种变体KD均≤270 μM。片段4配体效率0.44 kcal/mol,最大Tversky相似性0.62,作者认为可作为新型NNRTI先导片段。未报告RSD、稳定性或实际样品回收率。
传感器的构成
- 基底/换能器:CM5 SPR传感芯片(GE Healthcare),提供金基表面等离子共振换能表面
- 修饰层:CM5羧甲基葡聚糖(carboxymethyl dextran)胺偶联层,用于共价固定HIV-1 RT
- 识别元件:重组HIV-1逆转录酶(HIV-1 RT,wt或K103N/Y181C/L100I,E478Q),固定于芯片表面,与片段配体结合
- 运行缓冲液:PBS含5% DMSO和0.05% Tween 20,维持酶活性并降低非特异结合
- 信号读出:Biacore S51 SPR仪器,无标记检测结合引起折射率变化,输出sensorgram
中文摘要
本研究从含1040个片段的库中鉴定出一种可抑制野生型及耐药型人类免疫缺陷病毒1型逆转录酶(HIV-1 RT)的新型支架。通过Tversky相似性分析表明,库中片段与已知非核苷逆转录酶抑制剂(NNRTI)结构差异显著。作者采用表面等离子共振(SPR)生物传感器相互作用分析与酶抑制实验相结合的筛选策略:先以短浓度系列进行SPR初筛,再结合奈韦拉平竞争实验和酶抑制实验,鉴定结合于NNRTI结合位点并具有抑制活性的片段。共获得10个命中化合物,并测定其对野生型及K103N、Y181C、L100I三种耐药突变体的亲和力和耐药谱。其中一个片段对四种酶变体均表现出亚毫摩尔级KD和IC50值。将该片段与826个已发表NNRTI进行子结构比较,证实其支架具有新颖性。该片段为溴茚酮,配体效率为0.42 kcal/mol。
英文摘要
A novel scaffold inhibiting wild type and drug resistant variants of human immunodeficiency virus type 1 reverse transcriptase (HIV-1RT) has been identified in a library consisting of 1040 fragments. The fragments were significantly different from already known non-nucleoside reverse transcriptase inhibitors (NNRTIs), as indicated by a Tversky similarity analysis. A screening strategy involving SPR biosensor-based interaction analysis and enzyme inhibition was used. Primary biosensor-based screening, using short concentration series, was followed by analysis of nevirapine competition and enzyme inhibition, thus identifying inhibitory fragments binding to the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site. Ten hits were discovered, and their affinities and resistance profiles were evaluated with wild type and three drug resistant enzyme variants (K103N, Y181C, and L100I). One fragment exhibited submillimolar K(D) and IC(50) values against all four tested enzyme variants. A substructure comparison between the fragment and 826 structurally diverse published NNRTIs confirmed that the scaffold was novel. The fragment is a bromoindanone with a ligand efficiency of 0.42 kcal/mol(-1).